Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains)

Dalbavancin is an investigational lipoglycopeptide having an extended serum elimination half-life allowing once-weekly dosing. Data from testing 1357 strains of uncommonly isolated species expand the dalbavancin spectrum details as follows (MIC50/90): beta-haemolytic streptococcal serogroups C, F, and G (<= 0.03/<= 0.03 mu g/mL), 7 viridans group of streptococci (<= 0.03/<= 0.03-0.06 mu g/mL), 5 Corynebacterium spp. (0.06/0.12 mu g/mL), Listeria monocytogenes (0.06/0.12 mu g/mL), and Micrococcus spp. (<= 0.03/<= 0.03 mu g/mL). Among all reported isolates, 99.8% of tested strains were inhibited at dalbavancin MIC values at <= 0.12 mu g/mL. Dalbavancin remains very potent against rarer Gram-positive pathogens, using in vitro test experience with organisms cultured through 2011. (C) 2013 Elsevier Inc. All rights reserved.